依达拉奉联合腺苷钴胺治疗糖尿病周围神经病30例

Therapeutic Effect of Edaravone Combined Cobamamide in Treating Diabetic Peripheral Neuropathy

目的探讨依达拉奉联合腺苷钴胺治疗糖尿病周围神经病的疗效。方法纳入60例2型糖尿病并周围神经病患者,随机均分为联合组和腺苷钴胺组。腺苷钴胺组肌肉注射腺苷钴胺1.5 mg,每日1次,共28 d;联合组在此基础上同时静脉滴注依达拉奉30 mg,每日2次,共14 d。在治疗前后测受累神经传导速度,观察临床症状和不良反应。结果联合组临床症状好转率为86.67%,显效率为66.67%,神经传导速度好转率为83.33%,显效率为56.67%,腺苷钴胺组临床症状好转率为66.67%,显效率为36.67%,神经传导速度好转率为60.00%,显效率为30.00%。两组间临床症状和神经传导速度有效率、显著率比较差异均有显著性(P<0.05),均未出现严重不良反应。结论依达拉奉联合腺苷钴胺治疗糖尿病周围神经病较单用腺苷钴胺能够提高疗效。

Objective To observe the treatment effect of edaravone combined cobamamide for treating diabetic peripheral neuropathy（DPN）.Methods Sixty patients with DPN were included and divided into two groups randomly and equally.The cobamamide group was treated with cobamamide 1.5 mg by intramuscular injection,once daily for 28 d.On this base,the combined group was simultaneously treated with edaravone 30 mg by intravenous drip,twice daily for 14 d.The conduction velocity of involved nerve was detected before and after treatment,and the clinical symptoms and adverse reactions were observed.Results In the combined group,the improvement rate of the clinical symptoms was 86.67% and the excellence rate was 66.67%,the improvement rate of nerve conduction velocity was 83.33% and excellence rate was 56.67%.In the cobamamide group,the improvement rate of the clinical symptoms was 66.67% and the excellence rate was 36.67%,the improvement rate of nerve conduction velocity was 60.00% and excellence rate was 30.00%.The differences in the effective rate and excellence rate of the clinical symptoms and nerve conduction velocity between the two groups had statistical significance（P 0.05）.Both groups had no severe adverse reactions.Conclusion Edaravone combined cobamamide can increase the curative effect in treating DNP than using cobamamide alone.